FDA Opens the Door to Flavored Vapes: Why TBX VAPE FREE Is Now More Urgent Than Ever
The nicotine market just changed again, and not in a way that should make anyone comfortable.
In the United States today, approximately 18 million adults now use e cigarettes, while approximately 25 million adults still smoke cigarettes. That gap is no longer distant. It is narrowing. Cigarette use is declining, but nicotine addiction is not disappearing. It is moving into a new format, a more modern format, a more discreet format, and now a format that has received a significant new signal from the U.S. Food and Drug Administration. [1]
On May 5, 2026, the FDA authorized the marketing of 4 Glas electronic nicotine delivery system products through the PMTA pathway. Each authorized product is an e liquid pod containing 50 mg/ml, or 5%, of tobacco derived nicotine. The FDA stated: “This action marks the FDA’s first authorization of non-tobacco and non-menthol ENDS products.” [2]
That is the headline.
FDA has now authorized specific flavored vape products. It has not approved every flavored vape. It has not declared vaping safe. In fact, FDA expressly warns that authorized e cigarette products are not “FDA approved” and that “All tobacco products are harmful and potentially addictive.” [3]
But the regulatory meaning is still substantial. A category once viewed as facing broad uncertainty now has a clearer path for at least some flavored nicotine vape products to remain in the lawful adult marketplace.
That is not good news for nicotine addiction.
It may be very important news for the urgency of TBX VAPE FREE.
If flavored vapes are now moving into a more formal regulatory lane, then adult flavored nicotine use could continue to grow. The marketplace has already shown that vaping is expanding while cigarette smoking declines. CDC data shows adult e cigarette use increased from 4.5% in 2019 to 6.5% in 2023, and then reached approximately 7.0% in 2024. [4] At the same time, adult cigarette smoking fell to 9.9% in 2024. [1]
That creates a dangerous public health paradox.
America may be smoking less, but it is not necessarily becoming free from nicotine. Instead, millions of users are shifting from combustible cigarettes to electronic nicotine delivery systems. The device changes. The flavor changes. The social perception changes. The addiction remains.
This is exactly why TBX VAPE FREE needs to be in the market as quickly as the company’s clinical validation and regulatory strategy allow.
Vaping Could Surpass Cigarette Smoking Before 2030
The most alarming part of the current nicotine market is not simply that vaping is growing. It is that vaping is growing while cigarette smoking continues to decline.
In 2024, CDC data showed that 9.9% of U.S. adults used cigarettes, while approximately 7.0% used e cigarettes. [1] That means the gap between adult smokers and adult vapers has narrowed to less than 3 percentage points. A market that once looked like a cigarette market with a smaller vaping segment is now beginning to look like a nicotine market with 2 competing delivery systems.
If those directional trends continue, vaping could reach parity with cigarette smoking before 2030. Under a simple straight line projection using recent CDC prevalence trends, adult vaping could approach or surpass adult cigarette smoking as early as the second half of this decade.
That should concern anyone focused on nicotine addiction.
The public health story cannot be limited to the decline of cigarettes if nicotine dependence is simply moving into another product category. A lower smoking rate is not a full victory if millions of users are shifting into flavored, high nicotine electronic delivery systems. The format may be newer. The flavor profile may be more attractive. The device may be more discreet. But the dependency remains.
FDA’s recent authorization of specific flavored ENDS products makes that issue more urgent. The agency did not approve all flavored vapes, and it did not declare vaping safe. But the authorization signals that certain flavored vape products can remain in the lawful adult marketplace when FDA determines the required public health standard has been met. [2]
That changes the commercial reality.
If flavored vaping becomes more normalized, more regulated, and more available through lawful channels, adult use could continue to grow. That may accelerate the timeline toward parity with cigarette smoking. It may also increase the need for a serious nicotine free cessation option designed specifically for vapers.
The New Nicotine Problem Is Not The Same As The Old Smoking Problem
For decades, smoking cessation was built around cigarettes. Nicotine gum, nicotine patches, and nicotine lozenges were designed for a cigarette world. They were built around the idea of replacing nicotine with nicotine and gradually reducing dependency over time.
That model may help some users, but the nicotine market has changed.
Vaping is not just another version of smoking. It is a different behavioral pattern. It is more discreet. It can be used more frequently. It is often flavor driven. It is easier to integrate into daily routines. For many users, the attachment is not only chemical. It is sensory, behavioral, repetitive, and emotional.
That is why a serious vape cessation product must understand the vaping experience itself.
The CDC states: “No tobacco products, including e-cigarettes, are safe.” [5] The CDC also states that most e cigarettes contain nicotine and that “Nicotine is highly addictive.” [5] In other words, the central dependency mechanism remains active even when the delivery system changes from smoke to vapor.
The youth data makes the issue even more serious.
The CDC states: “E-cigarettes are the most commonly used tobacco product among U.S. youth.” [6] In 2024, 1.63 million U.S. middle and high school students currently used e cigarettes, and 87.6% of current youth e cigarette users used flavored e cigarettes. [6]
That matters because flavor is not incidental to the vaping market. Flavor is part of the experience. Flavor is part of the adoption pattern. Flavor is part of why vaping can become so behaviorally sticky.
The CDC also reports that “Most middle and high school students who vape want to quit.” [6] That sentence should define the next phase of the category. The issue is not simply that people vape. The issue is that many people who vape do not want to remain trapped in the cycle.
They need a pathway out.
Why TBX VAPE FREE Matters Now
This is where TBX VAPE FREE becomes strategically important.
Redwood Scientific Technologies is developing TBX VAPE FREE as a nicotine free oral thin film platform designed to support vaping cessation without introducing additional nicotine. The strategic point is straightforward. If the market is moving toward regulated flavored vape use, then the market also needs a credible nicotine free off ramp for people who want to quit vaping.
This is not a claim of clinical outcome. Redwood’s products are not currently being marketed or sold, and the company intends to complete controlled efficacy studies before commercial launch. But from a market standpoint, the alignment is becoming stronger.
FDA’s authorization of specific flavored ENDS products shows that flavored nicotine products may remain a durable part of the adult marketplace. CDC data shows adult vaping is rising while adult cigarette use declines. Youth data shows flavored vaping remains a serious concern. Global data shows vaping is no longer a fringe category.
The World Health Organization reported in 2025 that more than 100 million people worldwide are now vaping, including at least 86 million adults and at least 15 million children aged 13 to 15. WHO’s Etienne Krug stated: “E-cigarettes are fuelling a new wave of nicotine addiction.” [7]
That is the warning.
The world may be fighting cigarettes successfully in some markets, but nicotine is adapting. It is becoming electronic, flavored, portable, discreet, and increasingly normalized.
That means the need for TBX VAPE FREE is not theoretical.
It is immediate.
The Market Does Not Need Another Vape. It Needs An Exit From Vaping.
The next fight is not only against cigarettes. It is against nicotine dependence in all of its new forms.
If flavored vapes are now moving into a more formal regulatory lane, then cessation innovation must move just as quickly. The public health system cannot afford a world where cigarette use declines, but nicotine dependence simply migrates to flavored electronic products.
The goal should not be to trade smoke for vapor and call the problem solved.
The goal should be to help people move beyond nicotine altogether.
That is the central Redwood thesis.
The market is changing. The regulator has moved. Consumer behavior is shifting. Vaping is growing toward cigarette level relevance. Youth exposure remains a serious concern. Adult use is rising. Millions of users want to stop.
The next major category may not be another vape.
It may be the first serious nicotine free answer to vaping itself.
Sources and References
[1] U.S. Centers for Disease Control and Prevention, National Center for Health Statistics, Cigarette and Electronic Cigarette Use Among Adults by Urbanization Level: United States, 2024. CDC reported that in 2024, 9.9% of adults used cigarettes and 7.0% used e cigarettes.
[2] U.S. Food and Drug Administration, FDA Expands Market Access, Authorizes New ENDS Products, May 5, 2026. FDA stated: “This action marks the FDA’s first authorization of non-tobacco and non-menthol ENDS products.”
[3] U.S. Food and Drug Administration, E-Cigarettes, Vapes, and Other Electronic Nicotine Delivery Systems Authorized by the FDA. FDA warns that authorized e cigarette products are not “FDA approved” and that “All tobacco products are harmful and potentially addictive.”
[4] U.S. Centers for Disease Control and Prevention, National Center for Health Statistics, Electronic Cigarette Use Among Adults in the United States, 2019 to 2023. CDC reported that adult e cigarette use increased from 4.5% in 2019 to 6.5% in 2023.
[5] U.S. Centers for Disease Control and Prevention, Health Effects of Vaping. CDC states: “No tobacco products, including e-cigarettes, are safe.” CDC also states: “Nicotine is highly addictive.”
[6] U.S. Centers for Disease Control and Prevention, E Cigarette Use Among Youth. CDC states: “E-cigarettes are the most commonly used tobacco product among U.S. youth.” CDC also reported that 1.63 million U.S. middle and high school students currently used e cigarettes in 2024 and that 87.6% of current youth e cigarette users used flavored e cigarettes.
[7] World Health Organization, WHO Tobacco Trends Report: 1 in 5 Adults Still Addicted to Tobacco, October 6, 2025. WHO reported more than 100 million people worldwide are now vaping, including at least 86 million adults and at least 15 million children aged 13 to 15.
About Redwood Scientific Technologies, Inc.
Redwood Scientific Technologies, Inc. is focused on developing innovative nicotine free technologies designed to help smokers transition away from combustible cigarettes and nicotine based products. The company’s TBX FREE and TBX VAPE FREE platforms are designed to address the behavioral and sensory aspects of smoking cessation while eliminating nicotine.
Redwood has previously achieved large scale commercial distribution of its oral thin film technologies and continues to advance new solutions designed for the global smoking cessation market. With more than 1 billion smokers worldwide and increasing regulatory pressure on both cigarettes and vaping products, demand for effective nicotine free alternatives continues to grow.
Additional information about Redwood Scientific Technologies can be found at
Additional Company Disclosure
Redwood Scientific Technologies, Inc. is currently advancing the development of its nicotine free cessation technologies, including TBX FREE and TBX VAPE FREE. The company is in the process of completing required clinical validation through controlled research protocols.
Redwood’s products are not currently being marketed or sold. The company intends to complete a double blind placebo controlled efficacy study covering both product platforms prior to any commercial launch. These studies are designed to evaluate the effectiveness of the products in supporting smoking and vaping cessation and to provide data suitable for scientific publication.
Until those studies are completed and the company finalizes its clinical and regulatory strategy, Redwood Scientific Technologies does not offer these products for sale.
In addition, Redwood’s commercial strategy is structured as a business to business distribution model. The company does not sell products directly to end users or directly to consumers. Instead, Redwood intends to work through licensed distributors, healthcare partners, and institutional channels for future product distribution.
Forward Looking Statement Notice
Certain statements contained in this article constitute forward looking statements within the meaning of applicable securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Forward looking statements include, but are not limited to, statements regarding clinical studies, product development, regulatory strategy, commercialization plans, and market opportunities.
Readers and investors should not place undue reliance on forward looking statements, which speak only as of the date of publication.
This article is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities.